Charles River Laboratories International (NYSE:CRL) Price Target Raised to $200.00

Charles River Laboratories International (NYSE:CRL) had its target price increased by research analysts at Mizuho from $174.00 to $200.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Mizuho’s target price points to a potential upside of 2.18% from the company’s previous close.

CRL has been the subject of a number of other research reports. Argus set a $200.00 target price on Charles River Laboratories International in a research note on Monday, November 17th. Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their target price for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. TD Cowen dropped their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus price target of $195.93.

Charles River Laboratories International Price Performance

CRL opened at $195.73 on Thursday. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $200.58. The company has a 50 day moving average of $178.81 and a two-hundred day moving average of $164.72. The company has a market cap of $9.63 billion, a P/E ratio of -125.47, a P/E/G ratio of 6.90 and a beta of 1.63. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the previous year, the business posted $2.59 EPS. The business’s quarterly revenue was down .5% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brooklyn Investment Group increased its position in Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC boosted its position in Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the second quarter worth $29,000. Rothschild Investment LLC increased its holdings in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the third quarter valued at about $31,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).